Comment

  • 23 January 2017

    Eli Lilly aims to dominate the migraine market

    In January 2017, Eli Lilly acquired US-based specialty company CoLucid for approximately $960m, a 33% premium over CoLucid’s share price. The value of the deal highlights the substantial commercial opportunity...

Close
Close
Close

Go Top